SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as escalating geopolitical tensions, specifically potential US tariffs on European economies related to Greenland and a 'Board of Peace' initiative, spark significant market uncertainty. Community discussions are rife with expectations of a market dip, though many anticipate a swift 'buy the dip' recovery, recalling past instances of market resilience to tariff-related volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as renewed tariff threats and geopolitical statements from former President Trump regarding European allies and Greenland ignite market concern. While many anticipate a market dip, a strong 'buy the dip' sentiment persists among some traders, recalling past swift recoveries in the tech-heavy index.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending following recent international approvals for its cancer immunotherapies, notably in Saudi Arabia for lung cancer, alongside updated positive clinical study results. The community is enthusiastically discussing the potential of Anktiva to revolutionize cancer treatment and is vocal about perceived US FDA delays, which is fueling significant speculation around a short squeeze. Investors are expressing strong optimism regarding Dr. Soon-Shiong's strategic vision and the company's considerable growth trajectory.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund ($UNG) is trending as an intensifying Arctic air invasion across large parts of the US is forecast to drive a significant surge in heating demand. The community is buzzing about a potential short squeeze, given extreme short interest and the sudden shift to frigid weather, though acknowledging the commodity's notorious volatility. This immediate weather catalyst is compounded by emerging long-term demand narratives surrounding AI data centers.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF ($IWM) is a major talking point as investors debate its resilience amid ongoing discussions about potential tariffs and a highly anticipated Supreme Court ruling. Community sentiment points to a strong rotation from large-cap tech into small caps, with IWM consistently outperforming other major indices. Despite some skepticism regarding the profitability of its underlying holdings, traders are closely watching IWM's breakout performance and its implications for broader market dynamics.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to escalating U.S.-EU tariff tensions over Greenland, which has triggered a broad risk-off sentiment across the cryptocurrency market. This geopolitical uncertainty has led to substantial long liquidations, sparking community debate about Bitcoin's reliability as a safe haven asset, with some strategizing potential further declines and others viewing current levels as a buying opportunity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending due to significant uncertainty surrounding the Digital Asset Market Clarity Act, after its CEO withdrew support over concerns about stablecoin rewards and other provisions, leading to the Senate postponing a key hearing. Community discussion reflects frustration with the stock's underperformance despite broader crypto movements, with many debating if the CEO's stance is a strategic long-term win or a short-term blow for vital revenue streams.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending significantly as renewed geopolitical tensions intensify, primarily driven by discussions around potential US tariffs on European countries concerning Greenland. This has sparked community debate regarding gold's role as a safe-haven asset, with many anticipating further upside amid broader uncertainty and concerns over currency debasement, while others caution about an overextended rally. The ongoing criticism of the Federal Reserve's independence adds another layer of market uncertainty supporting precious metals.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is intensely trending as a wave of bullish analyst upgrades, touting its AI-powered AXON platform and e-commerce expansion, clashes with significant recent price declines. The community is actively debating whether these drops are market manipulation and recurring short attacks ahead of anticipated strong earnings, or if the stock is facing genuine overvaluation and sector-wide headwinds.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is actively trending following its recent shareholder meeting, where the approval of a massive increase in authorized shares and a controversial $200 million investment in MrBeast Industries sparked widespread debate. Many investors are expressing concerns over potential dilution and a perceived deviation from the core Ethereum strategy, especially given the no-show of expected speakers and the stock's decoupling from Ethereum's performance. The community is intensely discussing whether these strategic moves represent visionary growth or significant missteps by management, led by Tom Lee.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Micro Cap Biotech Secures $60M to Advance Alzheimer’s Treatment, Shares Surge

Alzheimer&#8217;s disease is the most common form of dementia, primarily affecting people over the age of 65. It progressively damages brain cells through the buildup of abnormal proteins (known as plaques and tangles) which destroy neurons and interfere with communication throughout the brain.Developing effective prevention or treatment remains extremely challenging because Alzheimer&#8217;s is driven by multiple interacting factors, including inflammation, genetics, and possibly infections, rather than a single cause. In addition, many therapies struggle to reach the brain due to its ...

Clinical stage biotech company Vaccinex’s ($VCNX) stock was up nearly 16% (1:54 pm ET) on Thursday afternoon after the company said it will provide an update on safety and efficacy data from its Alzheimer’s drug study, lifting retail sentiment.Rochester, N.Y.-based Vaccinex said it will present ‘promising’ new efficacy and safety data for a randomized, double-blind, phase 1b/2 SIGNAL-AD study for the treatment of Alzheimer’s disease. Its lead product candidate is related to studying pepinemab antibody, aimed at treating early stages of Alzheimer’s disease. The company’s last update on positive clinical findings from its SIGNAL-AD Phase 1b/2 trial were made in August.VCNX stock is up 19.53% this week.Retail sentiment on the stock turned ‘bullish’ (72/100) from ‘neutral’ (50/100) a week ago with message volumes climbing into the ‘high’ zone compared to ‘normal’ last week.<figure class="image"><img style="aspect-ratio:1308/370;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_24_at_10_54_58_PM_16e50ec661.png" alt="Screenshot 2024-10-24 at 10.54.58 PM.png" width="1308" height="370"><figcaption>VCNX sentiment meter as of 1:25 pm ET</figcaption></figure>Many Stocktwits users were optimistic about its prospects even though the company has faced headwinds this year due to a challenging macro environment for biotech companies.<stembedurl>https://stocktwits.com/Pbonk/message/590003737</stembedurl><stembedurl>https://stocktwits.com/Krystian_v/message/589974260</stembedurl>As on December 31, 2023, the company’s cash and cash equivalents and marketable securities stood at $1.5 million, down from $6.4 million as of Dec. 31, 2022. In Oct. 2023, the company raised $9.6 million from the sale of common stock and warrants.VCNX stock is down 71% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

The Rochester, N.Y.-based firm said it will present ‘promising’ new efficacy and safety data for the treatment of Alzheimer’s disease later this month.

Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

Equity

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

VCNX
Vaccinex Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VCNX News

VCNXVaccinex Inc